Keywords
How to Cite
Abstract
Ozempic (semaglutide), a glucagon-like peptide-1 (GLP-1) receptor agonist originally used in the treatment of type 2 diabetes, has generated interest as a new approach to reducing obesity, as studies point to a high efficacy in reducing systolic blood pressure in obese patients, weight loss and a slight reduction in diastolic blood pressure. The objective of this systematic review was to find out what are the possible adverse effects caused by Semaglutide in patients who do not have DM2, since there are still few studies regarding the toxicity of the drug in non-diabetic patients. According to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) guidelines, the databases of the Pubmed and Scielo libraries were systematically used for all studies in this review. Meta-analyses, systematic reviews and randomized clinical trials that addressed the topic between 2012 and 2023 were included. Although the analyzed studies demonstrated efficacy in the use of semaglutide, mainly in non-diabetic obese patients, adverse effects were observed, mainly gastrointestinal, among them there are vomiting, nausea, diarrhea and abdominal pain, mild to moderate, in all analyzed studies, and should be taken into account before using and indicating the drug. It is also necessary for health professionals to follow up more closely and take greater care with patients who already have some type of comorbidity and who may be affected by the adverse effects of the medication. More long-term studies on the use of Ozempic in non-diabetic patients are still needed to be more certain about its toxicity.
References
CORMAC, K., et al. "O Efeito da Semaglutida na Pressão Arterial em Pacientes sem Diabetes: Uma Revisão Sistemática e Meta-Análise". Journal of Clinical Medicine. 12, no. 3: 772. 2023. DOI: https://doi.org/10.3390/jcm12030772.
DAVIES, M., et al. STEP 2 Study Group. Semaglutide 2•4 mg uma vez por semana em adultos com sobrepeso ou obesidade e diabetes tipo 2 (STEP 2): um estudo de fase 3 randomizado, duplo-cego, duplo-dummy, controlado por placebo. Lancet. 13 de março de 2021;397(10278):971-984. DOI: 10.1016/S0140-6736(21)00213-0. Epub 2021 2 de março PMID: 33667417.
DENG, Y., et al. Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review. Therapeutic advances in chronic disease, 13, 20406223221108064. 2022. https://doi.org/10.1177/20406223221108064. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260566/.
GAO, X., et al. Eficácia e segurança da semaglutida na perda de peso em pacientes obesos ou com sobrepeso sem diabetes: Uma revisão sistemática e metanálise de ensaios clínicos randomizados. Farmacol frontal. 2022 de setembro de 14;13:935823. DOI: 10.3389/fphar.2022.935823. PMID: 36188627; PMCID: PMC9515581.
GOMES, H. K. B. C., TREVISAN, M. O uso do ozempic (semaglutida) como medicamento off-label no tratamento da obesidade e como auxiliar na perda de peso. Revista Artigos.Com. Vol. 29; e7498. bRASIL, 202. ISSN 2596-0253.
HADDAD, F., et al. A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications. Life (Basel). 2023, Apr 14;13(4):1012. DOI: 10.3390/life13041012. PMID: 37109541; PMCID: PMC10144237.
HALL, S., ISAACS, D., CLEMENTS, J. N. Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist. Clin Pharmacokinet. 2018 Dec;57(12):1529-1538. DOI: 10.1007/s40262-018-0668-z. PMID: 29915923.
MA, H., et al. Eficácia e segurança dos agonistas do receptor GLP-1 versus inibidores do SGLT-2 em pacientes com sobrepeso/obesidade com ou sem diabetes mellitus: uma revisão sistemática e meta-análise de rede. BMJ Aberto. 2023 Mar 7;13(3):e061807. DOI: 10.1136/bmjopen-2022-061807. PMID: 36882248; PMCID: PMC10008474.
RANG, H. P., et al. RANG & DALE: FARMACOLOGIA. 7a Edição. Rio de Janeiro (RJ). Elsevier, 2012.
RøDER, M. E. Clinical potential of treatment with semaglutide in type 2 diabetes patients. Drugs Context. 2019, Dec 2;8:212585. DOI: 10.7573/dic.212585. PMID: 31844422; PMCID: PMC6905643.
RUBINO, D. M. STEP 8 Investigators. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022 Jan 11;327(2):138-150. DOI: 10.1001/jama.2021.23619. PMID: 35015037; PMCID: PMC8753508.
RUBINO, D., et al. STEP 4 Investigators. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021, Abril 13;325(14):1414-1425. DOI: 10.1001/jama.2021.3224. PMID: 33755728; PMCID: PMC7988425.
SABBÁ, H. B. O., et al. Ozempic (semaglutida) para tratamento da obesidade: vantagens e desvantagens a partir de uma análise integrativa. Research, Society and Development, v. 11, n. 11. Brasil, 2022. DOI: http://dx.doi.org/10.33448/rsd-v11i11.33963.
SHI, A., et al. Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial. Adv Ther. 2021 Jan;38(1):550-561. DOI: 10.1007/s12325-020-01548-y. Epub 2020 Nov 7. PMID: 33159658; PMCID: PMC7854449.
SINGH., G., KRAUTHAMER, M., BJALME-EVANS, M. Wegovy (semaglutida): uma nova droga de perda de peso para controle de peso crônico. J Investig Med. 2022, Jan;70(1):5-13. DOI: 10.1136/jim-2021-001952. EPub 2021 27 de outubro. PMID: 34706925; PMCID: PMC8717485.
TAK, Y. J., LEE, S. Y. Eficácia e Segurança a Longo Prazo do Tratamento Anti-Obesidade: Onde Estamos?. Curr Obes. Rep 10, 14–30 (2021). DOI: https://doi.org/10.1007/s13679-020-00422-w.
TAN, H. C., DAMPIL, O. A., MARQUEZ, M. M. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis. J ASEAN Fed Endocr Soc. 2022;37(2):65-72. doi: 10.15605/jafes.037.02.14. Epub 2022 Aug 23. PMID: 36578889; PMCID: PMC9758543. Disponível em: https://pubmed.ncbi.nlm.nih.gov/36578889/.
WEGHUBER, D., et al. STEP TEENS Investigators. Once-Weekly Semaglutide in Adolescents with Obesity. N Engl J Med. 2022 Dec 15;387(24):2245-2257. DOI: 10.1056/NEJMoa2208601. Epub 2022 Nov 2. PMID: 36322838; PMCID: PMC9997064.
WILDING, J. P. H., et al. STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002. DOI: 10.1056/NEJMoa2032183. Epub 2021 Feb 10. PMID: 33567185.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Rebecka Marques Gomes Sagratzki , Suellen Souza da Silva, Auro Régio Rocha Mascarenhas , Carolline Sabino Póvoa , Eduarda Martins Souza , Jonathan Tavares Da Silva , Pedro Henrique Queiroz Dos Santos , Vinicios Batista Monteiro Silva , Maykon Jhuly Martins de Paiva